Base de dados : LILACS
Pesquisa : D02.886.778 [Categoria DeCS]
Referências encontradas : 28 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3 ir para página          

  1 / 28 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: lil-621521
Autor: Teles, Juliana Souto; Fukuda, Ellen Yukie; Feder, David.
Título: Warfarin: pharmacological profile and drug interactions with antidepressants / Varfarina: perfil farmacológico e interações medicamentosas com antidepressivos
Fonte: Einstein (Säo Paulo);10(1):110-115, jan.-mar. 2012. graf, ilus.
Idioma: en; pt.
Resumo: Oral anticoagulants are among the drugs with the greatest number of drug interactions. The concomitant use of several medications is a common practice in patients with cardiovascular problems, who often also present with depression; therefore, the probability of an interaction occurring between warfarin and the antidepressants is high, and may result in increased or decreased anticoagulant activity. Since the possible interactions between these two classes of drugs have been poorly explored in literature, with a risk to the patients who use them, we reviewed the pharmacology of warfarin and its possible interactions with antidepressants. Of the antidepressants analyzed, those that showed relevant effects on the interaction with warfarin were, in decreasing order: paroxetine, venlafaxine, fluoxetine, and duloxetine.

Os anticoagulantes orais estão entre as drogas com maior número de interações medicamentosas. O uso concomitante de vários medicamentos é uma prática comum em pacientes com problemas cardiovasculares, os quais frequentemente também apresentam depressão; assim, a probabilidade de ocorrer alguma interação entre a varfarina e os antidepressivos é bem expressiva, podendo resultar em um aumento ou uma diminuição da atividade anticoagulante. Como as possíveis interações entre essas duas classes de medicamentos se mostraram pouco exploradas na literatura, com risco aos pacientes que fazem uso delas, revisamos a farmacologia da varfarina e suas possíveis interações com antidepressivos. Dos antidepressivos analisados, os que apresentaram efeitos relevantes na interação com a varfarina foram, em ordem decrescente: paroxetina, venlafaxina, fluoxetina e duloxetina.
Descritores: Anticoagulantes/farmacologia
Antidepressivos/farmacologia
Varfarina/farmacologia
-Administração Oral
Anticoagulantes/efeitos adversos
Anticoagulantes/farmacocinética
Anticoagulantes/uso terapêutico
Biotransformação/efeitos dos fármacos
Cicloexanóis/farmacologia
/metabolismo
CYTOCHROME P-ALDEHYDES ENZYME SYSTEM/metabolismo
Interações Medicamentosas
Fluoxetina/farmacologia
Hemorragia/induzido quimicamente
Paroxetina/farmacologia
Tiofenos/farmacologia
Trombofilia/tratamento farmacológico
Vitamina K/antagonistas & inibidores
Varfarina/efeitos adversos
Varfarina/farmacocinética
Varfarina/uso terapêutico
Limites: Seres Humanos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME


  2 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-893136
Autor: Xuan, Jing; Wu, Xiu-Ping; Kwon, Tae-Geon; Kyung, Hee-Moon; Bing, Li.
Título: Effects of strontium ranelate on alveolar ridge morphology augmentation / Efectos del ranelato de estroncio en el aumento del rebforde alveolar
Fonte: Int. j. morphol;35(4):1328-1331, Dec. 2017. tab.
Idioma: en.
Projeto: Shanxi Province International Science and Technology; . Shanxi Province returned overseas students research.
Resumo: SUMMARY: The objective of this study was to compare the Primary and Secondary stability of immediate implant placement with Alveolar Ridge Augmentation (ARA) and Strontium Ranelate (SR) as aids to enhance the stability using Resonance Frequency Analysis (RFA). Fifty eight subjects ideal for immediate implants were assigned to two groups to compare the primary and secondary stability of the implant using Alveolar Ridge Augmentation and oral strontium ranelate. They were tested for primary stability on placement of the implant and after eight weeks of placement for secondary stability. The stability was measured using resonance frequency analysis. Both the procedures showed an improvement in the stability but the Alveolar Ridge Augmentation procedure showed a significantly better primary stability (P< .03) and the secondary stability (P<.00). The means of the implant stability quotient value (ISQ) for the Alveolar ridge augmentation procedure was 74.2 for primary stability, and 83.34 for secondary stability. With the enhancement of stability with both the procedures Alveolar Ridge Augmentation proved to be a better procedure to achieve successful results of an immediately placed implant.

RESUMEN: El objetivo de este estudio fue comparar la estabilidad primaria y secundaria de la colocación inmediata del implante con el aumento de reborde alveolar (ARA) y el ranelato de estroncio (SR) como ayudas para mejorar la estabilidad mediante el análisis de frecuencia de resonancia (RFA). Cincuenta y ocho sujetos, ideales para implantes inmediatos, fueron asignados a dos grupos para comparar las estabilidades primaria y secundaria del implante usando el aumento del reborde alveolar y el ranelato de estroncio oral. Se efectuaron pruebas de estabilidad primaria en la colocación del implante, y después de ocho semanas para la estabilidad secundaria. La estabilidad se midió utilizando análisis de frecuencia de resonancia. Ambos procedimientos mostraron una mejora en la estabilidad, sin embargo el procedimiento del aumento del reborde alveolar mostró una estabilidad primaria significativamente mejor (P <0,03) que la estabilidad secundaria (P <0,00). Las medias del valor de cociente de estabilidad del implante (ISQ) para el procedimiento de aumento de reborde alveolar fueron 74,2 para la estabilidad primaria y 83,34 para la estabilidad secundaria. Se observó una mejora de la estabilidad en ambos procedimientos, el aumento del reborde alveolar demostró ser un mejor procedimiento para lograr resultados exitosos del posicionamiento de implante inmediato.
Descritores: Tiofenos/farmacologia
Implantes Dentários
Retenção em Prótese Dentária
Aumento do Rebordo Alveolar/métodos
-Osseointegração
Responsável: CL1.1 - Biblioteca Central


  3 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-1001583
Autor: El-Sharkawy, Karam Ahmed; AlBratty, Mohammed Mofreh; Alhazmi, Hassan Ahmad.
Título: Synthesis of some novel pyrimidine, thiophene, coumarin, pyridine and pyrrole derivatives and their biological evaluation as analgesic, antipyretic and anti-inflammatory agents
Fonte: Braz. J. Pharm. Sci. (Online);54(4):e00153, 2018. tab, graf.
Idioma: en.
Resumo: Pyrimidine derivative 3 was afforded through the reaction of compound (1) with 5-ureidohydantion (2). Product 3 underwent a cyclization to produce fused pyrimidine derivative 7, although the latter product 7 was synthesized through one step via the reaction of compound (1) with 5-ureidohydantion (2) using another catalyst. Compound 3 was oriented to react with cyclic ketones 8a,b in the presence of elemental sulfur, salicylaldehyde (10), aryldiazonium chlorides 12a,b and ω-bromo-4-methoxy- acetophenone (14), which afforded, fused thiophene derivatives 9a,b, coumarin derivative 11, arylhdrazono derivatives 13a,b and 4-methoxyphenyl butenyl derivative 15, respectively. The latter product 15 was reacted with either potassium cyanide (16a) or potassium thiocyanide (16b) to form cyano and thiocyano derivatives 17a,b, respectively. Compound 17a underwent further cyclization to afford pyridopyrimidine derivative 19. Compound 15 was reacted with either hydrazine (20a) or phenylhydrazine (20b) to produce hydrazo derivatives 21a,b and these products were cyclize to produce pyrrole derivatives 23a,b. Finally, 5-ureidohydantion (2) was reacted with compounds 24a,b,c to afford pyrimidine derivatives 25a,b,c. The structures of the synthesized compounds were confirmed using IR, 1H NMR, 13C NMR and mass spectrometry techniques. Compounds 11 and 19 have promising as analgesic and antipyretic activities
Descritores: Piridinas/análise
Pirimidinas/agonistas
Pirróis
Tiofenos/análise
Cumarínicos/análise
-Antipiréticos
Analgésicos/classificação
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  4 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-888989
Autor: Rodrigues, TA; Sampaio Junior, AJB; Nunes, IDP; Cartágenes, MSS; Garcia, JBS.
Título: Effect of strontium ranelate on pain behavior in an experimental model of osteoarthritis
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;50(9):e6314, 2017. graf.
Idioma: en.
Resumo: Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis, with proven effects of decreasing the risk of fractures and an indication of reducing the progression of osteoarthritis (OA). This study aimed to investigate the effects of SrRan as either a prophylactic or a treatment drug, using an OA rat model to assess pain behavior. A monoiodoacetate (MIA)-induced knee joint OA model in Wistar rats was used. Thirty Wistar rats (both sexes, 60 days old) were distributed in five groups of 6 rats each: the control group, that received no intervention; a prophylactic group, that received oral administration of 25 mg·kg-1·day-1 of SrRan for 28 days before induction of OA; a group treated with 25 mg·kg-1·day-1 of SrRan for 28 days after OA induction; a group treated with 50 mg·kg-1·day-1 during 28 days after OA induction; and a group that received oral saline for 28 days after induction. The assessment of pain behavior was performed considering articular incapacitation (weight-bearing test), mechanical hyperalgesia (Randall Selitto test) and motor activity (rotarod test), on days 0, 7, 14, 21, and 28. This experiment did not yield a significant difference when comparing the group that received SrRan prophylactically with the groups treated with 25 or 50 mg·kg-1·day-1 and the group that received oral saline. Thus, SrRan did not provide analgesia in either treated rats or as a prophylactic drug with the tested doses. Higher doses should be tested further to achieve possible significant results.
Descritores: Conservadores da Densidade Óssea/uso terapêutico
Hiperalgesia/tratamento farmacológico
Osteoartrite do Joelho/tratamento farmacológico
Tiofenos/uso terapêutico
-Modelos Animais de Doenças
Ratos Wistar
Limites: Animais
Masculino
Ratos
Responsável: BR1.1 - BIREME


  5 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
ARANA-CHAVEZ, Victor Elias
Texto completo
Id: biblio-828046
Autor: Rosa, Jucely Aparecida da; Sakane, Kumiko Koibuchi; Santos, Karina Cecília Panelli; Corrêa, Vivian Bradaschia; Arana-Chavez, Victor Elias; Oliveira, Jefferson Xavier de.
Título: Strontium Ranelate Effect on the Repair of Bone Defects and Molecular Components of the Cortical Bone of Rats
Fonte: Braz. dent. j;27(5):502-507, Sept.-Oct. 2016. tab, graf.
Idioma: en.
Resumo: Abstract This study was conducted to evaluate the effects of treatment with strontium ranelate (SR) on the repair of bone defects and molecular components of bones in femurs. Adult female rats (n=27) were subjected to ovariectomy (OVX) or Sham surgery. Thirty days after surgery, a defect was made in the femur and the animals were then divided into three groups: OVX, SHAM and OVX+SR. Euthanasia was performed four weeks after the bone defect surgery. Repair in bone defect was assessed by computed microtomography (μCT) and chemical composition of cortical bone was analyzed by Fourier transform infrared (FTIR) spectroscopy and energy dispersive X-ray spectroscopy (EDS). The trabecular thickness (Tb.Th) of the newly formed bone in the OVX+SR group was significantly higher than that for the OVX group. The collagen maturity in the OVX+SR group was smaller than in the other two groups. In this group, a significant increase in the amount of strontium (Sr) and a decrease in the amount of calcium (Ca) embedded to bone tissue were also observed. Systemic treatment with SR improved microarchitecture of the newly formed bone inside the defect, but decreased cross-linking of mature collagen in cortical bone.

Resumo Este estudo foi conduzido para avaliar os efeitos do tratamento com ranelato de estrôncio (RE) na reparação de defeitos ósseos e componentes moleculares de ossos nos fêmures. Ratas adultas (n = 27) foram submetidas a ovariectomia (OVX) ou cirurgia Sham. Trinta dias após a cirurgia, um defeito foi feito no fêmur e os animais foram então divididos em três grupos: OVX, SHAM e OVX+RE. A eutanásia foi realizada quatro semanas após a cirurgia de preparo do defeito ósseo. A reparação do defeito ósseo foi avaliada por microtomografia computorizada (μCT) e a composição química do osso cortical foi analisada por espectroscopia de infravermelho de transformada de Fourier (FTIR) e espectroscopia por energia dispersiva de raios X (EDS). A espessura do osso trabecular (Tb.Th) recém formado no grupo OVX+SR foi significativamente maior que a do grupo OVX. A maturidade do colágeno no grupo OVX+SR foi menor do que nos outros dois grupos. Neste grupo, observou-se também um aumento significativo na quantidade de estrôncio (Sr) e uma diminuição na quantidade de cálcio (Ca) no tecido ósseo. O tratamento sistêmico com RE melhorou a microarquitetura do osso recém formado dentro do defeito, mas diminuiu a reticulação do colágeno maduro no osso cortical.
Descritores: Osso e Ossos/efeitos dos fármacos
Tiofenos/farmacologia
-Ovariectomia
Ratos Wistar
Espectroscopia de Infravermelho com Transformada de Fourier
Análise Espectral/métodos
Limites: Animais
Feminino
Ratos
Responsável: BR1.1 - BIREME


  6 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-774619
Autor: Arantes, Henrique Pierotti; Gimeno, Suely Godoy Agostinho; Chiang, Alan Y.; Bilezikian, John P.; Lazaretti-Castro, Marise.
Título: Incidence of vertebral fractures in calcium and vitamin D-supplemented postmenopausal Brazilian women with osteopenia or osteoporosis: data from Arzoxifene Generations Trial
Fonte: Arch. endocrinol. metab. (Online);60(1):54-59, Feb. 2016. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective Vertebral fracture is the most common osteoporotic fracture, affecting quality of life and increasing mortality. Epidemiological data on incidence of vertebral fracture are scarce in Brazil and throughout Latin America. Our aim was to determine vertebral fracture incidence and risk factors in a female Brazilian population. Subjects and methods Postmenopausal women with low bone mass were studied from the Brazilian placebo group of Arzoxifene Generations Trial (n = 974), followed for up to 5 years. The primary endpoint was new vertebral fractures, detected by X-Ray. Experimental design defined two strata: A. Osteoporosis or previous vertebral fracture with osteopenia; B. Osteopenia without previous fracture. Previous fracture, T-score, ionized calcium, alkaline phosphatase, creatinine and glucose were analyzed at baseline. Crude and adjusted incidence rates of vertebral fractures were estimated and Poisson regression model was used. Results Incidence rate was 7.7 (95% CI of 5.4 to 10.9) per 1,000 person-years (PY), increasing as a function of age. Women with new vertebral fractures had higher prevalence of previous nonvertebral fracture after menopause, were older and had lower lumbar spine (LS) T-score. Fracture risk increased by 46% for each unit reduction in LS T-score. Variables correlated with new vertebral fracture were age (p = 0.034), LS T-score, stratum A (p = 0.001 for both) and previous nonvertebral fracture after menopause (p = 0.019). In the final model, LS T-score was the strongest predictor. Conclusions Incidence rate of vertebral fracture of 7.7 per 1,000 PY. Age and previous fractures were associated with new vertebral fracture, but LS T-score was the most important predictor.
Descritores: Doenças Ósseas Metabólicas/complicações
Pós-Menopausa
Fraturas da Coluna Vertebral/epidemiologia
-Distribuição por Idade
Doenças Ósseas Metabólicas/tratamento farmacológico
Brasil/epidemiologia
Cálcio/uso terapêutico
Suplementos Nutricionais/estatística & dados numéricos
Seguimentos
Incidência
Osteoporose Pós-Menopausa/tratamento farmacológico
Piperidinas/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Fatores de Risco
Tiofenos/uso terapêutico
Vitamina D/uso terapêutico
Limites: Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Meia-Idade
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  7 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-758432
Autor: Silva, José Alexsandro; Guimarães, Geovani Pereira; Patriota, Yuri Basílio Gomes; Silva, Natan Emanuell de Sobral; Sousa, Carlos Eduardo Miranda; Mendonça Junior, Francisco Jaime Bezerra; Santana, Davi Pereira; Damasceno, Bolívar Ponciano Goulart de Lima.
Título: Desenvolvimento e validação de metodologias analíticas para quantificação de um derivado tiofênico em sistemas microemulsionados / Development and validation of analytical methodologies for measurement of a tiophene derivative in microemulsion systems
Fonte: Rev. ciênc. farm. básica apl;35(4), dez. 2015.
Idioma: pt.
Resumo: O presente trabalho teve por objetivo validar métodos por espectrofotometria UV-Vis e por CLAE para a análise quantitativa de um derivado do tiofeno, o 2-[(3,4-dicloro-benzilideno)-amino]-5,6-diidro-4H-ciclopen-ta[b]tiofeno-3-carbonitrila (5CN05) e aplicá-los no doseamento da molécula contida em microemulsões, Os métodos propostos foram validados conforme a Resolução 899/2003 da Agência Nacional de Vigilância Sanitária (ANVISA), O comprimento de onda de máxima absorção do fármaco 5CN05 foi detectado em λ max= 387nm, O método espectrofotométrico validado mostrou-se seletivo, apresentando linearidade na faixa de 3 a 16 µg.mL-1, coeficiente de correlação (r) igual a 0,9998 e limites de detecção e quantificação de 0,12 µg.mL-1 e 0,41 µg.mL-1, respectivamente, Para o método CLAE, observou-se linearidade na faixa de 0,1 a 3,0 µg.mL-1, r = 0,99915, limites de detecção e quantificação de 0,07 µg.mL-1 e 0,10 µg.mL-1 respectivamente, Para ambos os métodos, os parâmetros precisão, exatidão e robustez mostraram-se adequados para o uso pretendido, As metodologias propostas podem ser seguramente aplicadas para quantificação do 5CN05 em produtos farmacêuticos como microemulsões...

This study aims to validate methods of Uv-Vis) and HPLC for quantitative determination of a thiophene derivative, 2 - [(3,4-dichloro -benzylidene)-amino] -5,6-dihydro-4H-cyclopentyl-ta [b] thiophene-3- carbonitrile referred in this study as 5CN05, and apply them to quantify the 5CN05 in microemulsions. The proposed methods were validated according to the Resolution RE 899/2003 of the National Health Surveillance Agency (ANVISA). The 5CN05 was detected by UV-Vis at λ max= 387nm. The validated UVVis UVVis method proved to be selective, showing linearity in the range of 3-16 µg.mL-1, correlation coefficient (r) of 0.9998 and limits of detection and quantification of 0.12 µg.mL-1 and 0.41 µg.mL-1 respectively. For the CLAE method the linearity was observed in the range 0.1 to 3.0 µg.mL-1, r = 0.99915, limits of detection and quantification of 0.07 µg.mL-1 and 0.10 µg.mL-1 respectively. For both UV-Vis and CLAE methods, the precision parameters, accuracy and robustness were adequate for the intended use. The proposed methodologies can be safely applied to quantify the 5CN05 in pharmaceutical microemulsions products...
Descritores: Antifúngicos
Preparações Farmacêuticas
Tiofenos/análise
-Espectrofotometria/métodos
Limites: Seres Humanos
Responsável: BR33.1 - Divisão Técnica de Biblioteca e Documentação


  8 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-748272
Autor: Lima, Tainah P.; Farinatti, Paulo T.V.; Rubini, Ercole C.; Silva, Elirez B.; Monteiro, Walace D..
Título: Hemodynamic responses during and after multiple sets of stretching exercises performed with and without the Valsalva maneuver
Fonte: Clinics;70(5):333-338, 05/2015. graf.
Idioma: en.
Resumo: OBJECTIVE: This study investigated the acute hemodynamic responses to multiple sets of passive stretching exercises performed with and without the Valsalva maneuver. METHODS: Fifteen healthy men aged 21 to 29 years with poor flexibility performed stretching protocols comprising 10 sets of maximal passive unilateral hip flexion, sustained for 30 seconds with equal intervals between sets. Protocols without and with the Valsalva maneuver were applied in a random counterbalanced order, separated by 48-hour intervals. Hemodynamic responses were measured by photoplethysmography pre-exercise, during the stretching sets, and post-exercise. RESULTS: The effects of stretching sets on systolic and diastolic blood pressure were cumulative until the fourth set in protocols performed with and without the Valsalva maneuver. The heart rate and rate pressure product increased in both protocols, but no additive effect was observed due to the number of sets. Hemodynamic responses were always higher when stretching was performed with the Valsalva maneuver, causing an additional elevation in the rate pressure product. CONCLUSIONS: Multiple sets of unilateral hip flexion stretching significantly increased blood pressure, heart rate, and rate pressure product values. A cumulative effect of the number of sets occurred only for systolic and diastolic blood pressure, at least in the initial sets of the stretching protocols. The performance of the Valsalva maneuver intensified all hemodynamic responses, which resulted in significant increases in cardiac work during stretching exercises. .
Descritores: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Benzodioxóis/farmacologia
Neoplasias do Colo/tratamento farmacológico
Isoquinolinas/farmacologia
Inibidores de Proteínas Quinases/farmacologia
Tiofenos/farmacologia
Inibidores da Topoisomerase I/farmacologia
Ureia/análogos & derivados
-CHECKPOINT KINASE TEMEFOS
Replicação do DNA/efeitos dos fármacos
Sinergismo Farmacológico
HTABORTION, INCOMPLETE CELLS
Proteínas Quinases/metabolismo
Proteínas Serina-Treonina Quinases/metabolismo
Ureia/farmacologia
Limites: Seres Humanos
Tipo de Publ: Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  9 / 28 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-723119
Autor: Guimarães, Geovani Pereira; Reis, Mysrayn Yargo de Freitas Araújo; Silva, Dayanne Tomaz Casimiro da; Mendonça Junior, Francisco Jaime Bezerra; Converti, Attílio; Pessoa Jr, Adalberto; Damasceno, Bolívar Ponciano Goulart de Lima; Silva, José Alexsandro da.
Título: Antifungal activity of topical microemulsion containing a thiophene derivative
Fonte: Braz. j. microbiol;45(2):545-550, Apr.-June 2014. ilus, tab.
Idioma: en.
Projeto: PROCAD; . Coordination of High-Level Personnel Training (CAPES); . Science without Borders Program; . State of São Paulo Research Foundation; . National Council for Scientific and Technological Development (CNPq); . Center for Strategic Technology in the Northeast (CETENE); . Edital PROPESQ-UEPB.
Resumo: Fungal infections have become a major problem of worldwide concern. Yeasts belonging to the Candida genus and the pathogenic fungus Cryptococcus neoformans are responsible for different clinical manifestations, especially in immunocompromised patients. Antifungal therapies are currently based on a few chemotherapeutic agents that have problems related to effectiveness and resistance profiles. Microemulsions are isotropic, thermodynamically stable transparent systems of oil, water and surfactant that can improve the solubilization of lipophilic drugs. Taking into account the need for more effective and less toxic drugs along with the potential of thiophene derivatives as inhibitors of pathogenic fungi growth, this study aimed to evaluate the antifungal activity of a thiophene derivative (5CN05) embedded in a microemulsion (ME). The minimum inhibitory concentration (MIC) was determined using the microdilution method using amphotericin B as a control. The formulations tested (ME- blank and ME-5CN05) showed physico-chemical properties that would allow their use by the topical route. 5CN05 as such exhibited moderate or weak antifungal activity against Candida species (MIC = 270-540 µg.mL-1) and good activity against C. neoformans (MIC = 17 µg.mL-1). Candida species were susceptible to ME-5CN05 (70-140 µg.mL-1), but C. neoformans was much more, presenting a MIC value of 2.2 µg.mL-1. The results of this work proved promising for the pharmaceutical industry, because they suggest an alternative therapy against C. neoformans.
Descritores: Anti-Infecciosos Locais/farmacologia
Antifúngicos/farmacologia
Candida/efeitos dos fármacos
Cryptococcus neoformans/efeitos dos fármacos
Emulsões/farmacologia
Tiofenos/farmacologia
-Testes de Sensibilidade Microbiana
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  10 / 28 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-712695
Autor: Nardone, Valeria; D'Asta, Federica; Brandi, Maria Luisa.
Título: Pharmacological management of osteogenesis
Fonte: Clinics;69(6):438-446, 6/2014. tab, graf.
Idioma: en.
Resumo: Osteogenesis and bone remodeling are complex biological processes that are essential for the formation of new bone tissue and its correct functioning. When the balance between bone resorption and formation is disrupted, bone diseases and disorders such as Paget's disease, fibrous dysplasia, osteoporosis and fragility fractures may result. Recent advances in bone cell biology have revealed new specific targets for the treatment of bone loss that are based on the inhibition of bone resorption by osteoclasts or the stimulation of bone formation by osteoblasts. Bisphosphonates, antiresorptive agents that reduce bone resorption, are usually recommended as first-line therapy in women with postmenopausal osteoporosis. Numerous studies have shown that bisphosphonates are able to significantly reduce the risk of femoral and vertebral fractures. Other antiresorptive agents indicated for the treatment of osteoporosis include selective estrogen receptor modulators, such as raloxifene. Denosumab, a human monoclonal antibody, is another antiresorptive agent that has been approved in Europe and the USA. This agent blocks the RANK/RANKL/OPG system, which is responsible for osteoclastic activation, thus reducing bone resorption. Other approved agents include bone anabolic agents, such as teriparatide, a recombinant parathyroid hormone that improves bone microarchitecture and strength, and strontium ranelate, considered to be a dual-action drug that acts by both osteoclastic inhibition and osteoblastic stimulation. Currently, anti-catabolic drugs that act through the Wnt-β catenin signaling pathway, serving as Dickkopf-related protein 1 inhibitors and sclerostin antagonists, are also in development. This concise review provides an overview of the drugs most commonly used for the control of osteogenesis in bone diseases.
Descritores: Doenças Ósseas/tratamento farmacológico
Osteogênese/efeitos dos fármacos
-Anticorpos Monoclonais Humanizados/uso terapêutico
Conservadores da Densidade Óssea/uso terapêutico
Difosfonatos/uso terapêutico
Moduladores Seletivos de Receptor Estrogênico/uso terapêutico
Teriparatida/uso terapêutico
Tiofenos/uso terapêutico
Limites: Feminino
Seres Humanos
Masculino
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME



página 1 de 3 ir para página          
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde